Key result
Hydroxychloroquine started at 17 weeks in maternal SLE with anti-SSA yields normal fetal cardiac function.
Why the study?
Systemic lupus erythematosus primarily affects women of reproductive age and increases pregnancy risks, although management advances have improved maternal and fetal outcomes.
Does hydroxychloroquine prevent fetal complete heart block in a pregnant woman with SLE and anti-SSA (Ro) antibodies?
Case Report (n=1)
Does hydroxychloroquine prevent fetal complete heart block in a pregnant woman with SLE and anti-SSA (Ro) antibodies?
Early diagnosis of SLE and initiation of hydroxychloroquine in a pregnant woman with anti-SSA (Ro) antibodies and a history of fetal complete heart block was associated with a favorable fetal cardiac outcome.
Requires heightened fetal surveillance in SLE with prior CHB; leaves open optimal prevention strategies.
BACKGROUND: Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease that causes multi-organ damage and primarily affects women of reproductive age. Although pregnancy in these patients carries increased risks, advances in management have significantly improved outcomes for both the mother and the fetus. CASE PRESENTATION: A 32-year-old woman with a history of two stillbirths and an infant death due to a complete heart block (CHB) was referred at 17 weeks of gestation for fetal echocardiography, which showed no abnormalities. Further clinical evaluation revealed systemic features including painless mucosal ulcers, intermittent synovitis, and mild pericardial effusion. Positive anti-SSA (Ro) antibodies and a positive ANA test (1:80, homogeneous pattern) supported the classification of SLE. Hydroxychloroquine (HCQ) treatment was started, and follow-up echocardiograms revealed normal fetal heart function. The pregnancy progressed without complications, resulting in the birth of a healthy baby with normal cardiac findings. CONCLUSION: The diagnosis of SLE in this case was based on a combination of clinical manifestations and immunologic findings, in accordance with the ACR/EULAR 2019 criteria. While HCQ may have contributed to the favorable fetal outcome, spontaneous improvement or other modifying factors cannot be excluded. Early maternal assessment and timely initiation of treatment remain critical for optimizing outcomes in high-risk pregnancies.
No takes yet. Share an insight, caveat, or question.
Akbari et al. (2025) conducted a case report in Systemic Lupus Erythematosus (SLE) in pregnancy (n=1). Hydroxychloroquine was evaluated on Fetal cardiac function and pregnancy outcome. Initiation of hydroxychloroquine at 17 weeks of gestation in a pregnant woman newly diagnosed with SLE and anti-SSA (Ro) antibodies resulted in normal fetal cardiac function and the birth of a healthy baby.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: